On detecting viral RNAs, the RNA helicase retinoic acid-inducible gene I (RIG-I) activates the interferon regulatory factor 3 (IRF3) signalling pathway to induce type I interferon (IFN) gene transcription. How this antiviral signalling pathway might be negatively regulated is poorly understood. Microarray and bioinformatic analysis indicated that the expression of RIG-I and that of the tumour suppressor CYLD (cylindromatosis), a deubiquitinating enzyme that removes Lys 63-linked polyubiquitin chains, are closely correlated, suggesting a functional association between the two molecules. Ectopic expression of CYLD inhibits the IRF3 signalling pathway and IFN production triggered by RIG-I; conversely, CYLD knockdown enhances the response. CYLD removes polyubiquitin chains from RIG-I as well as from TANK binding kinase 1 (TBK1), the kinase that phosphorylates IRF3, coincident with an inhibition of the IRF3 signalling pathway. Furthermore, CYLD protein level is reduced in the presence of tumour necrosis factor and viral infection, concomitant with enhanced IFN production. These findings show that CYLD is a negative regulator of RIG-I-mediated innate antiviral response. Keywords: cylindromatosis; interferon; IRF3; RIG-I; ubiquitin EMBO reports (2008) 9, 930-936.
INTRODUCTION
Recognition of virus-derived nucleic acids by the DExD/H-box RNA helicases, the melanoma differentiation-associated gene 5 (MDA5) protein and the retinoic acid-inducible gene I (RIG-I) protein (Yoneyama et al, 2005) leads to the production of type I interferon (IFN) in most cell types. Both RIG-I and MDA5 contain caspase recruitment domains (CARDs) that interact with the CARD domain-containing protein interferon-b promoter stimulator 1 (IPS-1), also known as MAVS, VISA or Cardif, which resides on the outer membrane of mitochondria (McWhirter et al, 2005) . IPS-1, in turn, transduces signals leading to the activation of interferon regulatory factor 3 (IRF3), nuclear factor-kappaB (NF-kB) and activator protein 1 (AP-1) transcription factors (McWhirter et al, 2005) . IRF3 has a crucial role in antiviral response, as IRF3-deficient mouse embryonic fibroblasts have impaired IFNb production when infected (Sato et al, 2000) . IRF3 phosphorylation is mediated by the kinases TANK (TRAF family member-associated NFkB activator) binding kinase 1 (TBK1) and inhibitor-kB kinase e (IKKe; Fitzgerald et al, 2003; Sharma et al, 2003) . Precisely how IPS-1 activates TBK1 and IKKe remains unclear, and other molecules such as TANK, NEMO/IKKg and TRAF (TNF receptor-associated factor) family members have also been implicated in the IRF3 signalling cascade (McWhirter et al, 2005; Saha et al, 2006; Guo & Cheng, 2007; Zhao et al, 2007) .
The mechanism by which the IRF3 pathway is negatively regulated is poorly understood; however, accumulating evidence suggests that the attachment and removal of polyubiquitin chains might be important. Canonical Lys 48-linked polyubiquitination leads to proteasomal degradation, whereas non-canonical Lys 63-linked polyubiquitination seems to be crucial for signalling (Krappmann & Scheidereit, 2005) . A20, a molecule with both E3 ubiquitin ligase and deubiquitinase activity, has been shown to act as a negative regulator of RIG-I-mediated IFNb gene transcription (Wang et al, 2004; Lin et al, 2006) . RIG-I undergoes Lys 63-linked polyubiquitination (Gack et al, 2007) , suggesting that post-translational modification by ubiquitination is probably a crucial mechanism by which the IRF3 pathway can be regulated. Another known deubiquitinase that removes Lys 63-linked polyubiquitin chains is CYLD, a tumour suppressor which was originally identified as a genetic defect in familial cylindromatosis (Bignell et al, 2000) . CYLD acts as a negative regulator of NF-kB and Jun N-terminal kinase signalling pathways by removing Lys 63-linked polyubiquitin from NEMO/IKKg, TRAF2 and BCL3 (B-cell CLL/lymphoma3; Brummelkamp et al, 2003; Kovalenko et al, 2003; Trompouki et al, 2003; Massoumi et al, 2006) . Here, we report that CYLD interacts with components of the RIG-I pathway to inhibit IRF3 signalling and subsequent IFNb production.
RESULTS AND DISCUSSION CYLD interacts with RIG-I
Owing to the crucial role of RIG-I in the antiviral response, a search for RIG-I-interacting molecules was performed to uncover regulatory components of the pathway. In particular, molecules that regulate ubiquitination are of interest because of increasing evidence that this post-translational modification has a crucial role in signalling and immune responses (Liu et al, 2005) . Bioinformatic approaches were initially used to conduct the search. By using gene expression data from 79 human tissues (PMID: 15075390), we examined the tissue-and cell-type expression profiles of 47 genes encoding deubiquitinating enzymes (PMID: 12917690) and 31 genes encoding CARDcontaining proteins. Interestingly, both CYLD and RIG-I (also known as DDX58) show a similar expression profile across the 79 tissues and are significantly enriched in immune cells (Po0.0007 and Po0.0002, respectively, using the Wilcoxon rank-sum test; Fig 1A) , suggesting a possible functional association in immune pathways. Furthermore, the analysis of networks constructed from protein interaction data places CYLD and RIG-I within a functional cluster that is important for tumour necrosis factor (TNF) signalling (supplementary Fig 1 online) . This computational approach provides a discovery tool to find physical and functional associations between signalling molecules in antiviral responses that have not been previously appreciated.
To confirm the in silico analysis, Flag-tagged RIG-I and Myctagged CYLD were transfected into 293 Epstein-Barrvirus nuclear antigen (EBNA) cells, and a co-immunoprecipitation experiment was performed (Fig 1B) . Myc-tagged CYLD was detected in the anti-Flag immunoprecipitation from cells co-transfected with Flag-RIG-I, but not with a negative control Flag-tagged protein. This observation substantiates the bioinformatics analysis and establishes an interaction between RIG-I and CYLD. To test whether this interaction has functional relevance, the effect of CYLD expression on RIG-I-mediated response was tested by using a synthetic reporter consisting of multimerized PRDI (positive regulatory domain 1) sites derived from the IFNb promoter that responds to IRF3 activation (Yoneyama et al, 1996) . Ectopic expression of RIG-I was sufficient to activate the IRF3 reporter, and this response was inhibited by coexpression of CYLD but not of a control protein (Fig 1C) . We also observed interaction between endogenous CYLD and RIG-I after infection of 293 EBNA cells with Sendai virus Cantell (SeV; Fig 1D) . These data indicate a physical interaction between the two molecules and suggest that CYLD negatively regulates RIG-I and the antiviral response.
CYLD inhibits SeV-induced IFNb production
To test the above hypothesis, we investigated whether CYLD can modulate the response to SeV infection, which has been shown to trigger IFNb production in a RIG-I-dependent manner (Kato et al, 2005) . In control transfected cells, SeV infection induces a robust activation of the IRF3 reporter, but this effect was significantly inhibited in CYLD-transfected cells (Fig 2A) . A similar effect of CYLD was observed with a luciferase reporter containing the proximal promoter of IFNb with binding sites for IRF3, NF-kB and AP-1 (Thanos & Maniatis, 1992 ; Fig 2A) . These reporter assays suggest that CYLD might inhibit IFNb gene transcription in response to virus infection, which was confirmed by quantitative PCR analysis of IFNb messenger RNA (Fig 2B) . Finally, culture supernatants from infected cells were tested for IFN activity by using a bioassay that measures the ability of IFN to block replication of a green fluorescent protein (GFP)-tagged Newcastle disease virus (NDV). The supernatant from CYLD transfectants infected with SeV inhibited NDV-GFP replication to a lesser extent than the supernatant collected from control transfectants (Fig 2C; supplementary Fig 2A, B online) . This indicated that there was less IFN in the CYLD transfectants, which is consistent with the hypothesis that CYLD inhibits RIG-I-mediated IFN production. As a positive control, transfection of the Ebola virus VP35 gene also inhibited SeV-induced IFN production, as previously reported (Cardenas et al, 2006) . Cells transfected with CYLD also showed decreased SeV-induced IRF3 and I-kBa phosphorylation (supplementary Fig 2C,D online ).
Next, we tested the effect of CYLD loss-of-function using RNA interference. CYLD expression was efficiently knocked down by using a pool of four RNA duplexes (si-CYLD) when compared with control non-silencing oligonucleotides (si-NS; supplementary Fig 3A online ). Loss of CYLD expression led to an enhancement in SeV-triggered IRF3 and IFNb reporters (Fig 2D) , phosphorylation of IRF3 and IkBa (supplementary Fig 3C online) , and IFNb mRNA level ( Fig 2E) . Finally, CYLD knockdown led to enhanced SeV-induced IFN secretion (Fig 2F; supplementary Fig 3B online) . Owing to the possibility of off-target effects mediated by the si-CYLD Smartpool duplexes, we used an siRNA duplex that targets the 3 0 untranslated region (UTR) of the CYLD mRNA (si-CYLD UTR). The si-CYLD UTR had the same effect as the si-CYLD Smartpool on IFNb promoter activity, and the effect of the si-CYLD UTR was reversed by co-transfection of the CYLD open reading frame (supplementary Fig 3D online) , indicating that the effect of the si-CYLD is not due to an off-target effect. Taken together, these results support the hypothesis that CYLD is a negative regulator of the RIG-I-mediated antiviral response.
CYLD interacts with IPS-1, TBK1 and IKKe
Next, we examined whether CYLD can also interact with other molecules in the RIG-I signalling pathway, as this was suggested from network analysis (supplementary Fig 1 online) . Co-immunoprecipitation experiments were performed with the previously identified pathway components IPS-1, TBK1 and IKKe. Myctagged CYLD and Flag-tagged RIG-I, IPS-1, TBK1 or IKKe were co-transfected into 293 EBNA cells and, as shown in Fig 3A, CYLD interacted with all of the pathway components tested. Interestingly, the CYLD that coprecipitated with TBK1 and IKKe migrated as a doublet, suggesting that these kinases might be phosphorylating CYLD. However, when the stringency of the immunoprecipited wash buffer was increased from 250 to 500 mM NaCl, the interaction of TBK1 or IKKe with CYLD was no longer observed, suggesting that their interaction with CYLD is weaker than that of RIG-I and IPS-1. To establish a functional role for the observed interactions, we performed an epistasis experiment using the IRF3 and IFNb luciferase reporters (supplementary Fig 4A-D online) . The activation of both reporters by the constitutively active CARD of RIG-I (RIG-IN), IPS-1 and TBK1 was decreased by CYLD in a dosage-dependent manner. However, CYLD did not inhibit the IRF3 response induced by IKKe and seemed to be enhancing it, indicating that CYLD does not globally inhibit all IRF3 response. Similarly, IRF3 phosphorylation induced by overexpression of RIG-IN, IPS-1 and TBK1, but not IKKe, was also blocked by CYLD (Fig 3B) 5 online) . The difference in the sensitivity of TBK1 and IKKe to CYLD inhibition is notable in the light of recent studies showing that IKKe is not required for the initial IFNb induction by virus infection, but is required for the subsequent induction of antiviral genes by IFNb (Tenoever et al, 2007) . Thus, these observations are consistent with the idea that several molecules in the pathway, including RIG-I and TBK1, are targets of negative regulation by CYLD.
CYLD deubiquitinates RIG-I, TBK1 and IKKe
The removal of Lys 63-linked polyubiquitin chains from TRAFs and NEMO/IKKg by CYLD has been shown to inactivate the IKK complex that phosphorylates IkBa (Brummelkamp et al, 2003; Kovalenko et al, 2003; Trompouki et al, 2003) . As CYLD inhibits IRF3 signalling induced by RIG-I signalling components, we tested whether these components are targets for CYLD-mediated deubiquitination. 293 EBNA cells were transfected with fulllength RIG-I, RIG-IN, IPS-1, TBK1 or IKKe in conjunction with a ubiquitin mutant with only one lysine at position 63 available for conjugation (K63-Ub). Both full-length RIG-I and RIG-IN underwent Lys 63-linked polyubiquitination. TBK1 and IKKe were also modified but to a lesser extent, whereas IPS-1 did not undergo ubiquitination on ectopic expression (Fig 3C) . Ubiquitination of RIG-I, RIG-IN, TBK1 and IKKe was abrogated by coexpression of 4 online) , suggesting that ubiquitination is required for RIG-I and TBK1 to activate the IFN response, and that removal of ubiquitin by CYLD inhibits this. Recently, Lys 63-linked ubiquitination of Lys 172 of human RIG-I was reported to be required for RIG-I to associate with IPS-1 to induce IFN (Gack et al, 2007) ; the removal of this modification from RIG-I by CYLD might attenuate the response. The observations that CYLD can deubiquitinate TBK1 and inhibit the IRF3 response induced by TBK1 expression suggest that ubiquitination is also crucial for TBK1 function; however, it is unclear at present how attachment or removal of ubiquitin regulates the enzymatic activity of TBK1. Surprisingly, CYLD consistently reduced the amount of TBK1 protein and, to a lesser extent, that of full-length RIG-I and RIG-IN, whereas levels of IPS-1 and IKKe proteins were relatively unchanged. These observations suggest that the removal of Lys 63-linked polyubiquitin from RIG-I and TBK1 by CYLD might destabilize these molecules, and that this might be another mechanism by which CYLD downmodulates the IFN response.
Regulation of CYLD during infection
Negative regulatory proteins can function as negative feedback molecules to attenuate the response or they can function as 'brakes' that are removed to allow the response to be enhanced. To investigate which of the above mechanisms applies to CYLD, we analysed the CYLD expression level in response to virus infection alone or in conjunction with TNF stimulation. We focused on TNF as a co-stimulus, as the network analysis suggested that TNF is in close proximity to CYLD and RIG-I (supplementary Fig 1 online) , and it is known to potentiate IFNb production triggered by influenza infection (Matikainen et al, 2006) . TNF alone had no effect on CYLD protein level (Fig 4) , in contrast to that reported previously (Jono et al, 2004) . This discrepancy might be due to a difference in the cell lines used and stimulating conditions. SeV infection alone also had no effect, but infection in the presence of TNF markedly reduced the amount of CYLD inhibits RIG-I signalling C.S. Friedman et al CYLD protein (Fig 4) , coincident with enhanced IRF3 signalling (supplementary Fig 7 online ) and IFNb production (Fig 4) . This suggests that CYLD might be reduced as a mechanism to potentiate IFNb production during viral infection. In summary, we have shown the inhibitory role of CYLD in regulating type I IFN production during the RIG-I-mediated antiviral response. As IFN upregulates numerous IFN-stimulated genes (ISGs) crucial for antiviral defence, such as ISG15 and ISG56, CYLD probably attenuates the establishment of an antiviral state. The transient inhibition of the activity of CYLD by pharmacological agents might therefore provide a strategy to enhance antiviral responses.
METHODS
Analysis of gene expression across 79 tissues. Microarray data files were obtained from the Novartis GNF human expression atlas version 2 resource (PMID: 15075390), and expression values of 33,689 probe sets from the HG-U133A (Affymetrix, Santa Clara, CA, USA) platform and the GNF1H custom chip were analysed. The data set was normalized by using global median scaling and we filtered the data by excluding from the analysis probe sets with 100% 'absent' calls (MAS 5.0 algorithm) across all 79 tissues. The data set was further filtered by setting a minimum threshold value 420 in at least one sample for each probe set and a maximum mean expression value 4100. Hierarchical clustering (complete linkage method) was performed with Cluster 3.0 using Pearson's correlation as the similarity metric. Z-score transformation was applied to each probe set across all arrays before generating 'heatmaps' for visualization using TreeView. Interferon bioassay. The IFN bioassay was performed as described previously (Cardenas et al, 2006) . Conditioned supernatants (100 ml) from SeV-infected cells were subjected to ultraviolet irradiation to inactivate infectious SeV and overlaid onto Vero cells seeded in a 96-well black microtitre plate (Costar, Cambridge, MA, USA). After 24 h, the Vero cells were infected with the IFN-sensitive virus NDV-GFP for 1 h at an MOI (multiplicity of infection) of 6 in serum-free media. At 24 h after infection, GFP fluorescence was quantified in a FLUOstar OPTIMA plate reader (BMG Labtechnologies, Offenburg, Germany) set with excitation and emission wavelengths at 485 and 530 nm, respectively. The relative GFP unit for each sample was calculated using the formula (value of sampleÀvalue of background)/(value of highest sampleÀvalue of background) Â 100. Co-immunoprecipitation of endogenous proteins. A total of 1 Â 10 8 293 EBNA cells per sample were mock or SeV infected for 24 h and then lysed in an ice-cold buffer containing 1% CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate), 50 mM Tris, 150 mM NaCl, 5 mM MgCl 2 , pH 7.5 supplemented with protease inhibitors. Lysates were clarified by centrifugation at 10,000g at 4 1C and incubated for 2 h with 1 mg of CYLD antibody or normal mouse IgG. Immune complexes were precipitated for 30 min at 4 1C with 2.5 ml of protein A/G beads pre-blocked with BSA. Beads were washed three times with 1% CHAPS lysis buffer and then boiled in SDS sample buffer. Samples were resolved on SDS-PAGE and analysed by sequential blotting with anti-RIG-I and anti-CYLD. In vivo deubiquitination assay. Flag-tagged RIG-I signalling molecules were co-transfected with haemagglutinin-tagged Lys 63-Ub, and either vector or Myc-CYLD. After 24 h, cells were incubated with 25 mM MG132 for 4 h and then lysed in Triton lysis buffer. Lysates were denatured with 1% SDS at 100 1C for 5 min, immunoprecipitated with anti-Flag beads, eluted with Flag peptide and immunoblotted.
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